Chronic Asthma
Conditions
Keywords
asthma, biologics, biomarkers, nasal polyposis, eosinophils
Brief summary
Primary objective \- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment Secondary objective(s) * To study biomarkers variation post-treatment in patients with and without Nasal Polyposis * To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous * To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).
Detailed description
Open-labeled National, Multicenter Non-interventional on the therapeutic strategy, Prospective (longitudinal) Disease registry, 3 years of follow-up 1. Correlation between non-invasive T2 markers (FeNO, blood eosinophils) versus inflammatory markers in sputum (eosinophils, periostin, NO, etc.) 2. Cluster analysis in both cohorts. 3. Analysis of some treatable traits on asthma control in MEGA cohort (BMI, anxiety and depression scale, exercise). 4. To characterize exacerbations (numbers, ICU admissions, treatments compliance, etc). 5. Analysis of compliance with asthma medications. 6. Analysis of patients with phenotype T2-LOW in MEGA cohort. 7. Analysis of patients with undetectable total IgE ( \< 10 UI/L). 8. Role of microRNA in diagnosis, follow-up and variations after treatments. 9. Analysis of alarmins (TSLP, IL-33 e IL-25) and IL-6 in blood and sputum. 10. To Immunophenotype eosinophils by single-cell analysis in blood and sputum at baseline and post-biological treatment.
Interventions
DRUGAntiasthmatic
real-life
Sponsors
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Sanofi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
For the general asthma cohort (MEGA): * Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol/salbutamol or positive methacholine test) of several severities attended at participant centres * Already in follow-up in MEGA cohort * To participate in the study * Signed informed consent Inclusion criteria for asthma patients treated with biologics * Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg/day of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 \<80%/FEV1/FVC \<70+ACQ-5 score ≥ 1.5/ ACT \< 19 at inclusion and/or have experience any of the following events on the last year: treatment with systemic steroids/ hospitalization or emergency medical care visit for worsening asthma. * When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE \> 75 and \< 1500 UI * Patients already in follow-up in the cohort of patients treated with biologics * Willing to participate in the study * Sign informed consent
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between non-invasive T2 biomarkers versus biomarkers in sputum | at date of randomization and after one year of follow-up | biomarkers in blood (eosinophils, mRNA, periostine), exhaled nitric oxide (FeNO), sputum cell analysis and mRNA expression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of treatable traits on asthma control by ACT questionnaire | at date of randomization and after one, two and three years of follow-up | asthma control by Asthma Control Questionnaire (ACT) |
| To characterize asthma exacerbations. | at date of randomization and after one, two and three years of follow-up | number of exacerbations, type of exacerbation, ICU admissions, treatment compliance |
| Analysis of withdrawing asthma medications | at date of randomization and after one, two and three years of follow-up | percentage of anti-asthmatic medication withdrawn from the pharmacy in the electronic prescription with respect to that prescribed in your treatment |
| Analysis of patients with phenotype T2-LOW (IgE less than 75 kU/L, blood eosinophils less than 150 cells/μL, and FeNO less than 20 ppb) | at date of randomization and after one year of follow-up | number of exacerbations |
| Analysis of clinical outcomes, pulmonary function tests, biomarkers patients with very low total IgE ( < 10 UI/L) | at date of randomization and after one year of follow-up | Total IgE |
| Role of alarmins and IL-6 in the component of inflammation in asthma | at date of randomization and after one year of follow-up | measure of TSLP, IL-33 e IL-25 in blood and sputum |
| Role of microRNAs in asthma diagnosis and variations after different treatments | 1 year | expression of mRNAs in blood and sputum |
| Immunophenotype eosinophils | 1 year | single-cell analysis of eosinophils in blood and sputum at baseline |
| Stability of asthma phenotypes along the follow-up | at date of randomization and after one, two and three years of follow-up | % of eosinophils in sputum sample |
Countries
Spain
Contacts
CONTACTJoaquin S Sastre
STUDY_DIRECTORJoaquin Sastre
Fundacion Jimenez Diaz
Outcome results
None listed